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Abstract
Xenografts -as simplified animal models of cancer- differ substantially in vasculature and
stromal architecture when compared to clinical tumours. This makes mathematical model-
based predictions of clinical outcome challenging. Our objective is to further understand dif-
ferences in tumour progression and physiology between animal models and the clinic.
To achieve that, we propose a mathematical model based upon tumour pathophysiology,
where oxygen -as a surrogate for endocrine delivery- is our main focus. The Oxygen-Driven
Model (ODM), using oxygen diffusion equations, describes tumour growth, hypoxia and
necrosis. The ODM describes two key physiological parameters. Apparent oxygen uptake
rate (k0R) represents the amount of oxygen cells seem to need to proliferate. The more oxy-
gen they appear to need, the more the oxygen transport. k0R gathers variability from the vas-
culature, stroma and tumour morphology. Proliferating rate (kp) deals with cell line speciﬁc
factors to promote growth. The KH,KN describe the switch of hypoxia and necrosis. Retro-
spectively, using archived data, we looked at longitudinal tumour volume datasets for 38
xenografted cell lines and 5 patient-derived xenograft-like models.
Exploration of the parameter space allows us to distinguish 2 groups of parameters.
Group 1 of cell lines shows a spread in values of k0R and lower kp, indicating that tumours
are poorly perfused and slow growing.Group 2 share the value of the oxygen uptake rate
(k0R) and vary greatly in kp, which we interpret as having similar oxygen transport, but more
tumour intrinsic variability in growth.
However, the ODM has some limitations when tested in explant-like animal models,
whose complex tumour-stromal morphology may not be captured in the current version of
the model. Incorporation of stroma in the ODM will help explain these discrepancies. We
have provided an example. The ODM is a very simple -and versatile- model suitable for the
design of preclinical experiments, which can be modified and enhanced whilst maintaining
confidence in its predictions.
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Author Summary
Tumour-bearing animal models of cancer are needed to discover new drugs to treat can-
cer. We aim in this article to capture—through mathematics- some underlying phenom-
ena of tumour growth in animals. We propose a set of equations that, despite being very
simple, describe tumour growth, hypoxia and necrosis. Cells under low oxygen levels
change into a stress state called “hypoxia”, which will ultimately lead to tissue death, also
known as “necrosis” and “apoptosis”. Hypoxic cells undergo a variety of changes which
impact tumour growth, development, metastasis and -most importantly- response to ther-
apy. Hence, oxygen distribution is important. We simulate oxygen profiles to locate hyp-
oxic and necrotic tumour regions. Finally, this mathematical model allows us to compare
and classify animal models from a grounded and physiological perspective, rather than a
more convenient and empirical one. This will help us understand how well (or poorly) ani-
mal tumours mimic tumours in patients. The simplicity of our mathematical model allows
us to obtain more information out of the same animal sets without any further experi-
ments, hopefully saving time, money and animal usage.
Introduction
Mathematical modelling of biological systems is a powerful tool to contrast hypotheses, thus
enhancing our ways to interpret the often very complex data generated in drug discovery. In
cancer, mathematical modelling has been widely applied to describe both clinical and in vivo
preclinical tumours [1–3], however translation of animal data into the clinic remains still as a
challenging task [4].
Mechanistic mathematical models of cancer endeavour to understand biological phenom-
ena beyond its mere description. These models are based upon the gathering of cross-disciplin-
ary knowledge of the biological system in question. For example, to understand vessel
perfusion, you may need histological data, blood flow data and even evidence of the tumour
mechanics, plus a collection of assumptions [5,6]. Some of these models also include simple
drug effects [7] and more complex transient-stage drug models [8]. Also, some recent in silico
models have been applied to clinical data [9], though being often insufficiently translatable
across preclinical and clinical settings. Agent-based in silicomodels of tumour growth and pro-
liferation of vessels and lymph are useful to identify vessel architectures and their mechanisms
of progression [10,11], but, hitherto their validation using experiments are difficult.
The tumour microenvironment differs substantially between animal models and the clinic.
This has been shown to be a key factor for the lack of success in clinical outcome prediction
[12]. More specifically tumour-stroma interaction is said to be the main cause for tumour pro-
gression and metastasis [12]. Further, some in silicomodelling techniques, based on agent-based
and game theory between stromal-tumour cell populations have recently been discussed and
contrasted in vitro [13], although again with no insight towards animal-clinical translation.
Tumour pathophysiology
We hypothesise connecting tumour-stromal morphology to growth is an important step to
enable a description of the differences in preclinical and clinical tumours. In this first step, we
consider an avascular tumour analogous to a tumour nest surrounded by stroma, which is a
common morphology found in xenografted tumours. We hypothesise, that stromal and
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vascular phenotypes and morphologies influence delivery of nutrient and oxygen, and thereby
tumour growth [14–15].
Many novel therapeutic approaches endeavour to tackle cancer by systemic exposure to
agents (~chemotherapy). These approaches include encapsulation of small molecules (nano-
medicine), biologics, personalised therapy, immune therapy, antiangiogenics and many more.
Clinical outcome predicted from some of these therapeutic approaches tested in animals is
especially poor, mostly due to the poor understanding of differences in tumour pathophysiol-
ogy; e.g. antiangiogenic and nanomedicines [16–18]. Today only a handful of these drugs are
in the clinic [18], despite the very promising results observed in animals.
The tumour growth Oxygen-Driven Model (ODM)
Oxygen is an important molecule, whose uptake, utilisation, diffusion and metabolism in cells
have been thoroughly studied from a biological point of view [19–22]. A number of researchers
have simulated oxygen profiles along with other key aspects of tumour progression, like micro-
environment and biomechanics [23], also in a multiscalar manner [11]. Some of these mathe-
matical models have been validated in vivo [24]. However, this validation is demanding and
the results are unsuitable to be applied extensively in a drug discovery setting.
We aim for an in silico tumour growth model which describes aspects of the tumour patho-
physiology, with an emphasis on oxygen delivery as a surrogate for other molecules coming
from the vasculature. The mathematical model should contain information on hypoxic and
necrotic regions. Nonetheless, the key aspect is the comparability across animal models and to
the clinic. Its simplicity allows a concise estimation of the parameters with small data sets and
will be the first step to a deeper understanding of how stroma, vasculature and tumour interact
in preclinical biological models.
ODM development
The starting point of this in silicomodel stems from previous radial models [25], combined
with observations and models made on the relationship between oxygen and proliferation rates
[23,26,27]. In vitro doubling times are substantially shorter than in vivo [28] and clinical [29]
doubling times, which can be attributed to restricted delivery of nutrient and oxygen in vivo.
We also believe mathematical models do not fully exploit the potential of the data, by being
overly complex and having unidentifiable parameters [27]. In this sense, we developed an in sil-
icomodel evolving from large models of hypoxia, using geometric features of tumours and sim-
ple physical equations. More information on the development of the ODM and some further
investigations are explained in detail in the S1 Text.
Results
The ODM’s Mathematical Formulation
Table 1. Variable and parameter glossary.
Symbol Name Units Description
Vi Tumour volume cm
3 Tumour volume of each tumour layer
VHi Hypoxic volume cm
3 Volume of tumour layer being hypoxic
VNi Necrotic volume cm
3 Volume of tumour layer being necrotic
VT Tumour volume cm
3 Total tumour volume (VT = ΣiVi)
VTo Initial tumour volume cm
3 Total tumour volume at experiment start
(Continued)
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In silicomodel assumptions
We considered some common assumptions as a starting point, based on the literature:
• Tumour shape: spherical. In order to simplify the spatial discretisation the tumour is taken as
one dimensional, where r, the radius is the only spatial variable [7,25].
• O2 transport occurs by molecular random walk monotony, i.e. diffusionally. There is no con-
vection (flow is nearly stationary Re< 1) or active transport (no intermembrane active oxy-
gen transporters). Hereby Fick’s law of molecular transport is applicable [30].
• Time scale: O2 diffusion (~1min
-1) occurs on a faster timescale than cell division (~1day-1),
where oxygen has reached steady state between each cell division.[31].
• Homogeneous tissue: constant diffusion (Fick’s diffusion constant remains 1.9x10-6cm2/s, as
for (H+) [32], see also epithelial transmissibility of Oxygen 5.3x10-11(cm2.mlO2)/(s ml
mmHg) [33] and 3x10-10(cm2 mlO2)/(s ml mmHg)[34]). This assumption has been imple-
mented in many mathematical models including [35].
• Extracelullar matrix (ECM) is the paracellular connective tissue assumed to have oxygen par-
tial pressure of breast cancerous epithelial tissue, i.e. 60mmHg [36]. This parameter is a mere
orientation which implies a large variability between subjects and tissue origin, varying from
30 to 104 mmHg for functional epithelium [37].
• Blood flow accessibility occurs from the whole surrounding matrix of the tumour, from the
subcutaneous side of a xenograft and from the underlying hypervascularised adipose tissue.
• Proliferation correlates with oxygen levels, given that the efficiency of aerobic energy produc-
tion is 36 to 2 compared to the anaerobic glycolysis, even though there is a large upregulated
transport of glucose towards cytosol [38].
Table 1. (Continued)
Symbol Name Units Description
rT Proportional to Tumour
radius
cm rT ¼ VT 1=3
i Layer # -
n # of Layers -
PO2 ;i Oxygen Pressure mmHg Oxygen levels in each layer
PO2
max Blood Oxygen Levels mmHg Maximum blood oxygen levels at tumour periphery
t Time day Time elapsed after beginning of experiment
kp Proliferation rate (day
mmHg)-1
Rate at which cells divide. Cell-type dependent
kR
0 Apparent oxygen
uptake rate
cm-1 Apparent oxygen needed for cells to divide: kR
0 ¼ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃkR=Dp  3=4pð Þ1=3; because this expression always
appears as a product with rT, we include the 3=4pð Þ1=3 to reduce computational burden and the
presentation of the equations
kR Oxygen uptake rate day/cm
3 Oxygen needed for cells to divide
D Diffusion coefﬁcient cm2/day Ease of oxygen to diffuse
KH Hypoxia constant mmHg Sharpness of hypoxic switch
KN Necrosis constant mmHg Sharpness of necrotic switch
doi:10.1371/journal.pcbi.1004550.t001
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Mathematical formulation
As highlighted above, the ODM aims to describe the growth of xenografted tumours based
upon their pathophysiology. The structure of the model will be described in depth hereafter,
for which a graphical display is presented (see Fig 1A). Likewise, a sketch of the different steps
of the iterative process is shown in Fig 1B. The S1 Text gives a historical perspective of the
model and its evolution from previous models.
The ODM is composed of one non-linear differential equation (replicated in n number of
concentric shells) –to describe tumour growth- and 2 algebraic equations –to describe the par-
titions of hypoxia and necrosis. The main assumption of the ODM is that oxygen drives
growth in a proportional manner (see Eq (11)). Unlike for somatic tissue, tumours also create
their own growth factors and cytokines locally [39]. However, tumour progression is associated
with aerobic glycolysis [39,40], where blood is the only route of acquisition of oxygen. For that
reason, the ODM is oxygen-centric.
The main equation relies on the physics of oxygen diffusion in porous media, for which first
Fick’s and mass conservation laws were applied. Considering steady state, first order oxygen
uptake by cells, spherical geometry and diffusivity independent of the position, these equations
summarise in
d2PO2
dr2
¼ kR
D
PO2; ð1Þ
where kR is the oxygen uptake rate, D diffusion coefﬁcient, Po2 oxygen tension and r radius. Let
us consider boundary conditions dPO2
dr
jr¼0 ¼ 0 and PO2jr¼rT ¼ PO2maxðrTo; rTÞ, where PO2max is
the oxygen tension at peripheral tissues. Here, oxygen at the tumour boundary depends on ini-
tial tumour radius rTo ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃX
Voðt ¼ 0Þ3
q
and tumour radius at time t, rT ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃX
ViðtÞ3
q
; t > 0.
Now, we solve by the substitution of variables method, where z ¼ dPO2
dr
is an auxiliary variable,
Fig 1. The ODM. (A) ODM sketch. (B) ODM iteration block diagram. In each iteration, we calculate radius, oxygen profile and update the volume. Hypoxia
and necrosis are then calculated heuristically as proportions of the total volume.
doi:10.1371/journal.pcbi.1004550.g001
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thus Eq (1) results in two ﬁrst order ODEs,
dPO2
dr
¼ z; ð2Þ
dz
dr
¼ kR
D
PO2: ð3Þ
Integrating this with the set boundary conditions we obtain,
PO2 ¼ C  e
ﬃﬃﬃﬃﬃﬃﬃ
kR=D
p
rð1þ e2
ﬃﬃﬃﬃﬃﬃﬃ
kR=D
p
rÞ; ð4Þ
C ¼ PO2
maxðrTo; rTÞ
e
ﬃﬃﬃﬃﬃﬃﬃ
kR=D
p
rT ð1þ e2
ﬃﬃﬃﬃﬃﬃﬃ
kR=D
p
rT Þ
: ð5Þ
If we now define the apparent oxygen uptake rate as, kR
0 ¼ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃkR=Dp and remembering the
expression for the hyperbolic cosine, cosh(x) = (ex+e−x)/2, we can simplify it into
PO2 ¼ PO2maxðrTo; rTÞ 
coshðkR 0  rÞ
coshðkR 0  rTÞ
: ð6Þ
The tumour is considered to have a spherical shape, and we discretise space by dividing the
tumour into n spherical shells, labelled by the index i (see Fig 2). The dynamics at each shell
are described by its separate set of equations, hence the Eqs (11–14) are labelled by the shell
index i. Nevertheless, this spatial discretisation is far from trivial. In this case, we chose our spa-
tial discretisation to minimise the error between the spatial distribution of oxygen and assum-
ing constant concentration in each shell. For that reason, we discretised at exponentially
-rather than linearly- distributed radii as Fig 2 suggests.
Hereby, the drop of oxygen is constant for the whole tumour at any given time. We achieve
that by dividing the total drop of oxygen at a given time (DPO2;Total ¼ PO2jrT  PO2jr¼0) by the
Fig 2. Spatial discretisation. (A) comparison between linear (top) and exponential spatial discretisation (bottom). (B) example of spatial discretisation of 1–5
shells with constant oxygen drop.
doi:10.1371/journal.pcbi.1004550.g002
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number of shells (n),
DPO2;i ¼
DPO2;Total
n
; t; 8i: ð7Þ
Now, solving for Eqs (7) and (6) we obtain the following expression for the oxygen drop
DPO2;i ¼
PO2
maxðrTo; rTÞ
n
1 1
coshðkR 0  rTÞ
 
: ð8Þ
Since the oxygen relationship is now linear with i, the oxygen at each consecutive shell can
be defined from inside-to-outside or outside-to-inside. We arbitrarily chose to add up shells
from the innermost shell, resulting in
PO2;i ¼ PO2ðr ¼ 0Þ þ i  DPO2;i
¼ PO2maxðrTo; rTÞ 
1
coshðkR 0  rTÞ
þ i
n
1 1
coshðkR 0  rTÞ
  
: ð9Þ
Now, the concentration of the oxygen at the tumour boundary was considered to reduce
with the exposed surface area of the spherical tumour,
PO2
maxðrTo; rTÞ ¼ PO2max  VTo=VT
 2=3
; ð10Þ
with VTo ¼
P
Viðt ¼ 0Þ, VT ¼
P
ViðtÞ and oxygen at tumour periphery Po2max. Eqs (9) and
(10) give the ﬁnal equation for oxygen diffusion (Eq (12)).
Hypoxia and necrosis arise as a direct consequence of insufficient oxygen distribution [41].
We consequently describe them as “smooth switches” [42], described by saturable (sigmoid,
or “S” shaped) functions (similar to Michaelis-Menten equations, Eqs (13) and (14)). This
means that at a particular oxygen concentration, cells will become stressed (hypoxia), which
at a further stage will become necrotic. This is not set as a threshold (step (Heaviside) func-
tion) but as a smooth probabilistic process, so that at any point in the tumour there is a non-
zero probability to find any type of cell: normoxic, hypoxic or necrotic. For more information
on the derivation of the equations please see S1 Text. Also, a Matlab code script can be found
in S2 Text.
Summary of main equations
The main ODM equations derived from Eqs (1–10) are summarised below,
dVi
dt
¼ kp  PO2 ;i  Vi; ð11Þ
PO2;i ¼
PO2
max
n  coshðkR0  rTÞ
VTo=VT
 2=3
ðn iþ i  coshðkR 0  rTÞÞ; ð12Þ
VHi ¼
PO2 ;i
KH þ PO2 ;i
 Vi; ð13Þ
VNi ¼
PO2 ;i
KN þ PO2 ;i
 Vi: ð14Þ
Oxygen-Driven Tumour Growth Model
PLOS Computational Biology | DOI:10.1371/journal.pcbi.1004550 October 30, 2015 7 / 20
These equations are sufficient to describe the ODM, which is represented graphically in Fig
1A. The volume of each tumour shells (Vi) is calculated via Eq (11), which is the equation gov-
erning tumour growth, while Eq (12) is used to calculate the oxygen profile across the tumour
shells. The volume of the total tumour is the arithmetic sum of the shells, (VT = SiVi). Last, Eqs
(13) and (14) are twin expressions to calculate volumes of hypoxic and necrotic regions respec-
tively. A quick reference guide to the mathematical notation can be found in Table 1.
Tumour division is controlled by kp and the oxygen levels, which are calculated in the radial
direction for each time step. As a consequence, regions of low oxygen are hypoxic; regions of
no oxygen are necrotic.
The ODM fits growth curves, hypoxia and necrosis data identifiably
To validate the ODM, we used data published by Benjamin Ribba et al. [5] (see Fig 3A). In this
manuscript Ribba and colleagues developed an Odinary Differential Equation (ODE) logistic
model addressing necrosis, hypoxia, vessels and proliferating fractions. For the validation, they
utilised a single study of 15 athymic mice implanted subcutaneously with HT29 cells (Fig 3A).
Tumours were frequently measured and two to three mice were euthanized weekly for immu-
nohistochemical (IHC) analysis (necrosis and hypoxia) [5].
Our model prediction results are similar to those obtained by Ribba et al. The parameter val-
ues denoted reasonable standard errors (see Table 2). We assessed the identifiability through
the collinearity index (g ¼ 1sLast) and condition number (k ¼
s1
sLast
), where σlast,σ1 are the largest
and smallest values of the diagonal of the factorised normalised sensitivity matrix (see S1 Text
and [43]). Brieﬂy, the sensitivity matrix (S) will be normalised (~S ¼ S  ~y~Y) and then factorised
(~S ¼ U  S  VT), which diagonal of the factorised matrix (diag(S)) contains the elements σLast,
σ1. The values of collinearity index and condition number show that the system is locally iden-
tiﬁable (see S1 Text), are below the set thresholds (see Table 2). The rank of the Fisher Informa-
tion Matrix (FIM) is 4, which means that all 4 parameters are practically identiﬁable (Table 2).
Finally, the cost function or objective function (OF) was deﬁned as a least-squares weighed
Fig 3. Complete model fit ODM. (A) Results of the fit with data (extracted from paper by Ribba’s group [5]). The plot contains information for tumour volume,
hypoxia and necrosis for colon carcinoma cell line HT29. (B) Model fit for a data set containing IHC information on HIF1α for hypoxia at end of study point for
MCF7 tumours.
doi:10.1371/journal.pcbi.1004550.g003
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sum between necrotic, hypoxic and proliferating regions,
minVOF ¼
P
t
X
r
ð ~V t;r  Vt;rÞ

Nr
ð15Þ
Where ~V t;r and Vt,r represent the estimated and measured volumes at each time point t and at
each tumour region r = {T,H,N}. Nr is the number of data points available for each region. In
the tables the residual is expressed as the solution of Eq (15).
This data fit demonstrated that the ODM describes, with sufficient accuracy, the hypoxic
and necrotic regions. However, in practice these data sets are difficult to obtain, because it
requires the sacrifice of animals at each time point in order to harvest the tumour for histologi-
cal analysis.
Online imaging studies of hypoxia using PET tracers can efficiently record multiple time
points [44] of hypoxia, however, they depend upon immobilisation of the animal and are
expensive. To meet economic requisites, some studies are designed to obtain one single hyp-
oxia measurement per tumour at the end of study. One time point is not sufficient to fit a
model with confidence. Nevertheless, it can provide an estimate of the parameter range. As an
in house example, we used a study in the breast cell line MCF7 with a single end-of-study hyp-
oxic point (from HIF1α staining). The ODM fits the data identifiably even though the data set
has been substantially reduced (see Table 2 and Fig 3B).
Faster vs Slower Growing Xenografts differ in growth rate, necrosis,
vessels and stroma
Motivated by the observed doubling times in different models (xenograft ~1week, explant
~weeks and human ~months or years), we divided the cell lines into Faster and Slower Grow-
ing Xenografts (FGX and SGX respectively, see Fig 4A–4D). The growth rate was windowed by
dividing the ranges of tumour growth across all cell lines and dividing it into SGX<0.05cm3/
day and FGX>0.05cm3/day. Fits to xenograft data were better than in explants (Fig 4A and
4B). Note that the last data point presented in Fig 4B shows a logistic trend. This behaviour is
captured in the ODM by means of the oblique asymptote dictated by the parameters kp and kR
0,
however there are restrictions to the complete saturation (see model in S1 Text for a more
diverse model).
We investigated the relationship between pathophysiology and growth rate in Colo205 as a
SGX (Fig 4D) and Calu6 as a FGX (Fig 4C). In general, more stroma is recruited in SGX and
necrosis appears further away from the vessels (Fig 4C and 4D). Mean vessel density (MVD),
vessel and lumen area in Calu6 showed reduced values compared to Colo205 (Fig 4E), suggest-
ing there is a relationship between pathophysiology and growth rate in xenografts, also
observed across explants and the clinic (Fig 6C).
The growth patterns of forty two cell lines and five explant-like models
are described by different ODM parameter values
After validation of the ODM dynamics with rich datasets, we explored a larger range of cell
lines with restricted data. We fitted the ODM to control data from 38 cell lines from various
pre-existing projects (see Table 3). However, in this case, hypoxia and necrosis data were not
available, therefore we fixed the parameters θf = {KH,KN} 2 <2 to the values observed in Fig 3
(the system would be insensitive to the parameters and thus non identifiable). Our selected
subset of parameters is then y^ ¼ fkp; k0Rg 2 <2, which will provide an idea of the variable inter-
play between delivery and cell line intrinsic factors over a series of models.
Oxygen-Driven Tumour Growth Model
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Parameter values for the proliferating rate lie in the range kp = 0.0001–0.0043mmHg
−1day−1
and in the range k
0
R ¼ 2 17cm1 for the oxygen uptake rate (see Fig 5A). Standard errors are
always comparable to the parameter values, suggesting that there is inter-animal variability. In
those cases a mixed effects model would be advisable.
Fig 4. Growth curve fit for 2 example xenografts. Panels (A-B) show fits of the model for Calu6 and Colo205. The plots also include simulation of hypoxia
and necrosis. (A) is a faster proliferating tumour model (Calu6) and (B) grows slightly slower (Colo205). (C-D) CD31 IHC staining in Calu6 and Colo205
respectively. (E) summary data of CD31 for both tumour models.
doi:10.1371/journal.pcbi.1004550.g004
Oxygen-Driven Tumour Growth Model
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Fig 5. Results of parameter estimates. (A) Parameter space (kp-k
0
R) for different tissue of origin lines. (B) Same as (A) but divided into Fast, Medium, Slow
and Very Slow Growth Xenografts. (C) Parameter space for explant-like tumour models.
doi:10.1371/journal.pcbi.1004550.g005
Table 2. Parameter results (kP, k
0
R, KH, KN) for the ODMmodel for Ribba et al. [5]. Data and MCF7 with
hypoxic endpoint.
Ribba 2010 MCF7
kp (mmHg x day)
-1 0.0058 0.0027
SE(kp) (mmHg x day)
-1 0.0041 0.0027
k0R cm
-1 13.37 7.54
SEðk 0RÞ cm-1 2.39 1.90
KH mmHg 25.9 13.8
SE(kH) mmHg 54.0 27.3
KN mmHg 20.2 -
SE(kN) mmHg 3.8 -
Rank - 312 342
Y - 49 35
k - 4 3
Residual - 0.18 0.09
doi:10.1371/journal.pcbi.1004550.t002
Oxygen-Driven Tumour Growth Model
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We note the collinearity index and condition number are well within the identifiable range.
Residual errors show appropriate goodness of fit. We identified a posteriori 2 groups of param-
eters within the dashed boxes. Group 1 parameters cluster in the lower range of kp and demon-
strate a wider spread over k
0
R, this group contains the slowest growing cell lines. Besides, k
0
R
Table 3. Parameter results (kp and k
0
R) for the ODMmodel in xenografts. Conﬁdence intervals for each parameter are speciﬁed as well as the rank of the
FIM (as a measure of the number of identiﬁable parameters), the collinearity index (Identiﬁable if γ<10), the condition number (Indentiﬁable if κ<1000) and the
normalised residual. Cell lines denoted by * are unidentiﬁable and cell lines denoted by # are arguably identiﬁable.
kp SE(kp) k
0
R SEðk0RÞ ΔV κ γ Rank Residual
(mmHg x day)-1 (mmHg x day)-1 cm-1 cm-1 cm3/day - - - -
Repr. Sys. Lung Calu6* 0.0001 0.0018 5.06 <0.01 0.10 529500 17874 2 0.20
Colon Colo205 0.0005 0.0014 3.17 2.24 0.03 46 9 2 0.10
Lung H460 0.0041 0.0035 13.38 3.08 0.14 135 10 2 0.30
H1975# 0.0013 0.0020 6.05 2.21 0.05 43 21 2 0.06
H3255 0.0001 0.0012 2.83 17.08 0.03 6 3 2 0.02
A2058 0.0005 0.0030 6.26 16.02 0.07 8 4 2 0.07
PC9 0.0003 0.0008 8.23 41.11 0.03 3 1 2 0.15
A549b 0.0001 0.0026 3.22 22.90 0.06 11 2 2 0.03
Breast HCC1954# 0.00005 0.0004 1.40 2.40 0.06 19 15 2 0.01
Cervix ME180# 0.0003 0.0014 3.20 3.39 0.03 14 21 2 0.02
Gastrointestinal Gastric SNU5# 0.0004 0.0011 3.35 2.32 0.04 56 17 2 0.04
SGC31 0.0002 0.0015 6.59 34.59 0.05 8 4 2 0.03
SGC37 0.0005 0.0031 8.51 46.99 0.01 9 1 2 0.15
SGC70 0.0008 0.0045 11.64 28.99 0.05 13 2 2 0.21
SGC71 0.0005 0.0043 7.46 29.73 0.08 11 2 2 0.08
SGC100 0.0002 0.0041 3.06 53.31 0.08 7 1 2 0.02
SGC161# 0.0005 0.0016 3.33 2.63 0.04 31 28 2 0.02
SGC181# 0.0005 0.0019 2.69 2.58 0.03 35 32 2 0.01
SGC184# 0.0002 0.0028 4.22 5.70 0.03 89 19 2 0.03
MKN45# 0.0006 0.0013 4.03 2.49 0.05 64 18 2 0.03
HS746T 0.0007 0.0050 9.68 36.93 0.04 9 1 2 0.15
Colon MC38# 0.0043 0.0047 17.19 3.94 0.13 93 15 2 0.11
Lovo 0.0009 0.0040 14.87 26.75 0.24 10 2 2 0.23
HCT116 0.0002 0.0029 4.93 40.20 0.11 10 1 2 0.07
HT29# 0.0011 0.0021 4.30 2.23 0.06 84 16 2 0.04
Other Skin A375# 0.0022 0.0018 11.71 2.88 0.06 139 12 2 0.19
Bladder MGHU3# 0.0035 0.0036 7.81 1.99 0.09 77 12 2 0.26
Kidney RCC47 0.0002 0.0003 6.85 3.47 0.00 4 11 2 0.51
786O# 0.0004 0.0007 4.68 2.31 -0.01 33 14 2 0.06
Blood KMS11 0.0002 0.0022 5.85 35.80 0.07 11 1 2 0.08
Lymph HT1080 0.0030 0.0028 8.52 1.98 0.07 78 10 2 0.36
Ri1 0.0002 0.0027 3.32 34.28 0.07 6 1 2 0.06
RS411 0.0003 0.0024 12.42 25.71 0.12 16 2 2 0.18
OCLy10* >100 - >100 - 0.03 >10000 >1000 2 0.04
OCLy19 0.0002 0.0044 4.17 25.02 0.12 17 2 2 0.04
A20 0.0003 0.0004 7.31 2.55 0.01 14 5 2 0.57
Mouse CT26 0.0003 0.0032 3.07 33.56 0.03 9 2 2 0.09
Stem cell ECB1 0.0001 0.0011 1.63 27.49 0.04 4 1 2 0.04
doi:10.1371/journal.pcbi.1004550.t003
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parameter values in Group 2 are found dispersed around an average of 12 cm-1, whereas kp
demonstrates large range of values; we identify this group with the faster growing cell lines (Fig
5B). However, the tissue of origin showed not to be predictive of the tumour growth rate.
Regrouping the cell lines in terms of growth rates, we found that kp is often the main driver
of growth speed, whereas k
0
R seem to vary across a range of values. The medians for both
parameters are 0.0023 mmHg-1 day-1 and 16.0 cm-1 respectively.
The explants used here and the cell line Calu3 present with a stromal vessel (SV) phenotype
(as described by Smith and co-workers [15]), thus we referred to them as explant-like models
in the present manuscript. This phenotype is more complex than typical xenografts (Tumour
Vessel phenotype [15]) and more reliably resembles the stromal complexity the clinical carci-
nomas of interest, where a mature vasculature surrounded by pericytes and myofibroblasts is
commonly found. The explant-like tumours range kp = 1–710−4day−1mmHg−1 (in the range
of very slow growing xenografts) and k
0
R ¼ 0:9 7:8cm1(similar to the xenografts, see Fig
5D) with the exception of colon 1.
As an exception, some cell lines (Calu6 and OCLy10) were not practically identifiable (see
Table 3); other cell lines were poorly identifiable (786O, A375, MGHU3, HT29, MC38,
MKN45, SGC161, SGC181, SGC184, ME180, H1954, H1975). This was partly because of the
quality and quantity of the data (some of these datasets include only 2 data points or contain
Fig 6. Growth curve fit for explants. (A) Growth curve fit for 4 explant models, 2 for squamous lung carcinoma and 2 for colorectal carcinoma. The
xenografted cell line Calu3 shows very similar behaviour to explant models. (B) Comparison between Calu6 and Calu3 lung cell lines; a squamous lung
cancer explant; and clinical tumour material analyses. The bar chart shows the proportions of microvessel density (MVD) in area (quantified from CD31),
necrosis (quantified from Hematoxylin & Eosin staining) and stroma (alpha smooth muscle actin (αSMA) positive staining). (C) Images of the different tumour
models stained for αSMA and counter-stained with hematoxylin.
doi:10.1371/journal.pcbi.1004550.g006
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experimental errors). Parameter values are within ranges observed for the other cell lines, but
the confidence intervals are very wide.
ODM does not always succeed in describing the growth pattern of
tumours with more complex pathophysiologies
In an effort to extend the application of the model, we applied the ODM to five explant-like
models. These models can be very heterogeneous in pathophysiology, an effect that may also be
evident in the growth curves. Results of the model-data fit are acceptable, but generally worse
than in xenografts (Fig 6A). However, lung 2 explant is poorly fitted on a point by point basis.
At this stage, growth curves alone are insufficient to understand pathophysiological differ-
ences between preclinical and clinical models. We stained tissue sections of the following
tumours: Calu6 (n = 8), Calu3 (n = 7), one squamous cell lung cancer explant (n = 28) and squa-
mous cell lung clinical cancers (n = 12) from AstraZeneca databanks. Both cell lines are derived
from non-small cell lung cancer. We observed that the microvessel density (MVD) increases
steadily from 0.4% in Calu6 to 4% in clinical tumours. We also looked at the tumour-associated
stromal cells (stained with αSMA), i.e. pericytes and myofibroblasts. These are the main stromal
cells contributing positively to tumour development. We highlight the 0.8% of αSMA staining
in Calu6 versus a range between 10–17% in the other models (Fig 6B), over 1 order of magni-
tude lower (also observed in Fig 6C). Lastly, the appearance of necrosis decreases from Calu6 to
clinical tumours, with the exception of Calu3. This analysis of histological data (Fig 6) allows us
to identify that even if the growth curves are similar, the tumour composition might play an
important role in the tumour behaviour and treatment. Further, the very large standard error
observed in Table 4 for k
0
R, demonstrate that the complex growth dynamics introduced by the
tumour microenvironment are captured by the oxygen uptake rate (k
0
R).
Introduction of stroma in the ODMmay be used to describe tumour-
stroma interaction
As showed in the histological data (Fig 6), clinical tumours have a complex microenvironment,
very different to the xenografts. One of the main differences observed is the tumour stroma. There-
fore, we adapted the model by adding one compartment for the formation of stroma (Fig 7A).
Initially, the stroma is recruited from distant sites of the body and is partly triggered by the
immune response. The connection between the desmoplastic (stroma formation) and angio-
genic (blood vessel formation) reactions has been identified in a series of animal models and
clinical metastases [45], but not accurately understood. As a first approximation, we assumed
that stroma by default carries vessels. Also, cancers trigger an inflammatory response, quickly
recruiting cells from distant sites of the body [40], similar to a “wound that never heals”.
Hence, we considered that the stroma is recruited proportionally to the volume of the “wound/
Table 4. Parameter results (kp and k
0
R) for the ODMmodel in explant-like tumours.
kp SE(kp) k
0
R SEðk0RÞ ΔV κ γ Rank Residual
(mmHg x day)-1 (mmHg x day)-1 cm-1 cm-1 cm3/day - - - -
Calu3 0.0001 0.0014 0.90 64.90 0.0007 10 11 2 <0.01
Lung 1 0.0003 0.0021 5.38 71.27 0.0005 6 1 2 0.10
Lung 2 0.0001 0.0003 4.78 2.45 0.0008 12 42 2 0.01
Colon 1 0.0007 0.0023 7.86 38.37 8.711 7 8 2 0.04
Colon 2 0.0001 0.0009 1.88 54.24 0.0096 9 3 2 0.03
doi:10.1371/journal.pcbi.1004550.t004
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cancer” (VT) with proportionality constant ks. This assumption requires thorough biological
support and refinement.
The stroma also triggers a modification in the proliferation rate kp(mmHg
−1day−1), which
turns into kPG(mmHg
−1 day−1 cm−3) = kPkG. This assumption stems from one of the hall-
marks of cancer, stating that tumour-associated stroma provides the key paracrine signals for
tumour development [46]. With these modifications, the model Eq (11) becomes Eq (16),
while Eq (17) is added.
dVi
dt
¼ kPG  PO2 ;i  Vi  VS ð16Þ
dVS
dt
¼ kS 
X
Vi ð17Þ
We ﬁtted this model to the Calu3 data explant, showing very good ﬁt (parameters for hyp-
oxia and necrosis remain ﬁxed). Stroma constituted around 30% of the tumour volume in the
prediction. However, this is a marginally identiﬁable case with very wide conﬁdence intervals
(Table 5).
Discussion
We have demonstrated that large data sets for hypoxia and necrosis along with tumour volume
are uniquely fitted with 4 parameters. This is a small number compared to other models, e.g. 6
parameters in the model by Ribba et al. [5]. In practice, data sets may not be as rich, having
Fig 7. ODM adaptation. (A) Sketch of the ODMmodel (oxygen dependent, left) as described here plus a single compartment (Stroma) (VS, oxygen
independent, right). Where kS is the stroma recruitment constant and kG is the growth enhancement constant. (B) Example of cell line fit for Lung 1 explant
model. Tumour volume over time and hypoxia at end of study are presented. Also a simulation of necrosis is presented.
doi:10.1371/journal.pcbi.1004550.g007
Table 5. Parameter results (kPG, k
0
R, kS) for the ODMmodel for Lung 1 explant model data.
kPG SE(kPG) k
0
R SEðk0RÞ ks SE(kS) Rank γ κ Residual
(mmHg x day x cm3)-1 cm-1 mmHg
- - - -
0.005 0.154 23.7 84.9 0.07 0.05 3 85 16122 0.04
doi:10.1371/journal.pcbi.1004550.t005
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reduced number of time points describing hypoxia. However, we typically find end-of-study
analysis of hypoxia and necrosis, which can be uniquely identified (Fig 3B), but arguably used.
To date, most models found in preclinical oncology are either empirical or implement non-
allocated compartments to describe hypoxic/necrotic regions. In the ODM, the calculated con-
tinuous spatial oxygen distribution dictates growth, hypoxia and necrosis, key physiological
parameters. This may be easily extrapolated to drug studies.
Growth rates increase in a quasi-monotonic fashion from the clinic, through to explants,
into xenografts. Typically, slower proliferating tumours develop more stroma and the vascula-
ture is more mature (Fig 6C). These tumours are, in general, also less necrotic. This is, although
a generalisation based on a few observations. Though, we hypothesise this could apply to many
cell lines, this has not been fully explored yet and we encourage other scientists to investigate it.
We have aimed for a more informative model using pathophysiological assumptions, how-
ever, the interpretation of the parameters can be further discussed. We postulate that the
model parameters signify:
KH, KN—hypoxia and Necrosis switch constant. These constants account for the variability in
the transition to hypoxia and necrosis;
kp—proliferation rate constant: natural frequency of cell division, in other words an in vivo
expression of the in vitro doubling time (free of delivery burdens). We expect kp to capture
genetic properties of the cell to commit to the cell cycle;
k
0
R—oxygen uptake rate: oxygen needed by each cell to divide. In our definition k
0
R should cap-
ture the microenvironment characteristics. It may also account for angiogenesis, in other
words the “apparent oxygen reach”. In short, k
0
R angiogenic values (1–70 cm
-1) are much
lower than the avascular hypothetical calculations (~200–400 cm-1 (Table 2)). This means
that oxygen appears to reach further than reported in the literature. This may be identified
with angiogenesis (see Fig F in S1 Text).
Since both parameters describe different aspects of the tumour physiology, we have aimed
to group the parameter space according to the sensitivity of both parameters, finding only very
weak associations and no differential affinity to organ of origin (e.g. lung) or cell type (e.g.
carcinoma).
On the one hand, Group 1 with a range of values of k
0
R and low kp, suggests that microenvi-
ronment plays a major role in the development of these tumours. Also, their growth rates are
slow. Similarly, explants demonstrate almost identical parameter values, being indicative of
growth, but not of physiology.
On the other hand, Group 2 with a k
0
R mean very close to the median values, indicates that
most medium to fast proliferating cell lines are better perfused and the tumour matrix is mainly
a mixture of sparse stromal and vascular cells. From our experience, these fast growing cells
trigger angiogenesis faster, but the immaturity of the vessels, combined with the competition
for space of the fast growing cells, leads to occluded vessels, which trigger unexpected necrosis
(IHC example shown on Fig E in S1 Text). These observations need to be revisited and sup-
ported with further evidence.
Explant-like models, which more closely model clinical pathophysiology, provided poor fits
to the ODM (Fig 6A). We suggest incorporating stroma and vasculature in the model to
address this problem. Evidence indicates that slower growing models, such as explant-like (also
referred as SV) tumours, rely on the recruitment of stroma to grow, followed by reduced necro-
sis and significantly greater MVD (as elucidated by the results, Fig 6B and 6C). The ODM
assumes a simple spherical morphology, which can mimic semi-vascular tumour nests in
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explant-like tumours. In future versions, we will capture stromal morphology from IHC images
and describe it spatially in a 3D version of the ODM. Despite the actual limitations of the
ODM so far, xenografts are properly described. The ODM, being a very simple model, captures
several aspects of the tumour pathophysiology in xenografts, namely proliferating rate, blood
effective perfusion, hypoxia and necrosis. However, the ODM fails to describe explant models
fully. This will be amended in more advanced versions of the ODM, which will mimic complex
tumour-stromal interactions. This will increase our understanding of animal models, thereby
enhancing preclinical decision making and pharmacokinetic and pharmacodynamic (PKPD)
predictions in humans.
Materials and Methods
Ethics statement
All studies were conducted in accordance with UK Home Office legislation, the Animal Scien-
tific Procedures Act 1986 (ASPA) and with AstraZeneca Global Bioethics policy. The analysis
in this paper is retrospective, utilising control/untreated animals of different oncology projects
within AstraZeneca between 2004 and 2013. All experimental studies have gone through the
AstraZeneca Ethical Review Process. All tumour volumes, animal weights and welfare were
maintained within the margins fixed by UK and European regulations. No data was generated
specifically for this manuscript.
Animals and cell lines
We used data from 38 xenografted cell lines implanted in the SCID and nude mice of both
sexes. Briefly, 1 x 106 to 1 x 107 human cancer cells, with or without Matrigel, were implanted
subcutaneously on the mouse flank. Tumour volumes were calculated from bisecting calliper
measurements using the prolate spheroid approximation formula [47]. Tumours were mea-
sured 1–3 times weekly.
Parameter estimation
The optimisation was done with a least-square multiple start global optimiser. The 150 initial
estimates for the simulation were selected randomly within a feasible parameter space by the
latin hypercube rule.
Differential-Algebraic Equation (DAE) solver
We solved our deterministic model Eqs (11–14) with a marquart-leuven integrator for stiff ode
solvers (matlab, ode15s). The Jacobian was calculated by direct analytical derivation of the
DAEs.
Sensitivity methods
We analysed all possible aspects of the model comparing and contrasting its structural and
practical identifiability, testing a variety of scenarios. We applied a Taylor Series approach to
evaluate structural identifiability [27,48] to ensure that there was a unique correspondence
between model parameter values and the model prediction over time. For practical identifiabil-
ity, we applied a model-based method calculating collinearity index and condition number
[43], broadly validated for various mathematical biology applications [49]. The standard errors
were calculated with the covariates (diagonal of the covariance matrix, where Co = FIM−1),
being Co the covariance matrix and FIM the Fisher Information Matrix (FIM = S−1 × S).
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Histopathology and image processing
The morphologies of explants and clinical tumours were determined from formalin-fixed par-
affin-embedded tissue sections. The tumour sections were then stained for CD31, αSMA, CC3
or HIF1α, counter-stained with Carazzi’s hematoxylin, and subsequently scanned. Images have
been colour deconvoluted to highlight the main features (stroma and epithelium). Finally, the
images were quantified with Aperio Microarrays, Genie and ColorDeconvolution algorithms.
Software and hardware
We used a Windows 7, Intel Exon (R) CPU E5-26200@ 2 x 2 GHz with Matlab 2013b (Math-
works, Massachusetts, USA) and the global optimisation toolbox.
Supporting Information
S1 Text. Remarks on the mathematical formulation of the model and extra comments to
the results.
(PDF)
S2 Text. Script with the ODE model.
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